The present non-clinical study shows that gedatolisib, a pan-PI3K/mTOR inhibitor, exerts greater anti-proliferative and cytotoxic effects than single-node PAM inhibitors such as everolimus in the EC, OC, and CC cancer cell lines, regardless of their PAM pathway mutational status. This evidence concerns the gene PIK3CG and cancer.